Payload Information
General Information of This Payload
| Payload ID | PAY0EQYST |
|||||
|---|---|---|---|---|---|---|
| Name |
Vinblastine
|
|||||
| Synonyms |
vinblastine
Click to Show/Hide
|
|||||
| Formula | C47H60N4O9 |
|||||
| Isosmiles | CC[C@@](C1)(O)C[N@@]2CCC(C3=CC=CC=C3N4)=C4[C@](C5=C(OC)C=C(N6C)C([C@]7([C@]6([H])[C@](C(OC)=O)(O)[C@@H]8OC(C)=O)CCN9CC=C[C@]8(CC)[C@@]79C[H])=C5)(C(OC)=O)C[C@H]1C2 |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C47H60N4O9/c1-9-43(55)24-29-25-45(40(53)58-7,37-31(16-20-50(26-29)27-43)30-14-11-12-15-34(30)48-37)33-22-32-35(23-36(33)57-6)49(5)38-46(32)18-21-51-19-13-17-44(10-2,42(46,51)4)39(60-28(3)52)47(38,56)41(54)59-8/h11-15,17,22-23,29,38-39,48,55-56H,9-10,16,18-21,24-27H2,1-8H3/t29-,38+,39+,42-,43-,44-,45-,46-,47-/m0/s1
|
|||||
| InChIKey |
PFISQCILBIBWDU-YXOGRGCXSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
825.016 |
Polar area |
154.1 |
||
Complexity |
2323.236826 |
xlogp Value |
4.381 |
|||
Heavy Count |
60 |
Rot Bonds |
8 |
|||
Hbond acc |
12 |
Hbond Donor |
3 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Percent Inhibition (%) | -11.33 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -11.69 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -5.21 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -9.3 | % |
HEK293 cells
|
Normal
|
||
| Tumor Growth Inhibition (TGI) | 0 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 0 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 0 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 0 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.001 | ug.mL-1 |
HCT116 cells
|
Colon carcinoma
|
||
| Median Effective Dose (ED50) | 0.001 | ug ml-1 |
HEp-2 cells
|
Laryngeal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.002 | ug.mL-1 |
A549 cells
|
Lung adenocarcinoma
|
||
| Median Effective Dose (ED50) | 0.002 | ug ml-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Median Effective Dose (ED50) | 0.002 | ug ml-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.005 | ug.mL-1 |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.0086 | ug.mL-1 |
KB 3-1 cells
|
Cervical epithelial carcinoma
|
||
| Median Effective Dose (ED50) | 0.01 | ug ml-1 |
SK-MEL-2 cells
|
Melanoma
|
||
| Median Effective Dose (ED50) | 0.01 | ug ml-1 |
Col2 cells
|
Colon carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.0102 | ug.mL-1 |
PC-12 cells
|
Adrenal phaeochromacytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.018 | ug.mL-1 |
L929 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.02 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.02 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Median Effective Dose (ED50) | 0.02 | ug ml-1 |
Lu1 cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Median Effective Dose (ED50) | 0.02 | ug ml-1 |
HT cells
|
Diffuse large B-cell lymphoma
|
||
| Median Effective Dose (ED50) | 0.02 | ug ml-1 |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.025 | ug.mL-1 |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.03 | ug.mL-1 |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.03 | ug.mL-1 |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.046 | ug.mL-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.047 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.047 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Median Effective Dose (ED50) | 0.05 | ug ml-1 |
A-431 cells
|
Skin squamous cell carcinoma
|
||
| Median Effective Dose (ED50) | 0.05 | ug ml-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Median Effective Dose (ED50) | 0.06 | ug ml-1 |
BC1 cells
|
Primary effusion lymphoma
|
||
| Median Effective Dose (ED50) | 0.1 | 10'-4 ug/ml |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Median Effective Dose (ED50) | 0.1 | ug ml-1 |
LNCaP cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.1 | ug.mL-1 | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.1 | ug.mL-1 |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Median Effective Dose (ED50) | 0.1 | 10'-4 ug/ml |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.15 | ug.mL-1 |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.22 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.22 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Median Effective Dose (ED50) | 0.3 | ug ml-1 |
ZR-75-1 cells
|
Invasive breast carcinoma
|
||
| Cell-based Percent Inhibition (%) | 0.36 | % | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.46 | ug.mL-1 |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.46 | ug.mL-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Median Effective Dose (ED50) | 0.5 | ug ml-1 |
KB-V1 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.52 | ug.mL-1 |
COLO 320DM cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.52 | ug.mL-1 |
COLO 320 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 0.6 | cm | Undisclosed | Undisclosed | Undisclosed | |
| Median Effective Dose (ED50) | >1 | ug ml-1 |
Vero cells
|
Normal
|
||
| Median Effective Dose (ED50) | >1 | 10'-1 ug/ml |
Vero cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.02 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.08 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Median Effective Dose (ED50) | 1.1 | ug ml-1 |
U-373MG ATCC cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.15 | ug.mL-1 |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.22 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.37 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.45 | ug.mL-1 |
WRL68 cells
|
Embryonic hepatoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.45 | ug.mL-1 |
WRL68 cells
|
Embryonic hepatoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.6 | ug.mL-1 |
COLO 320DM cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.6 | ug.mL-1 |
COLO 320 cells
|
Colon adenocarcinoma
|
||
| Median Effective Dose (ED50) | 1.7 | ug ml-1 |
P388 cells
|
Lymphoma
|
||
| Cell-based Percent Inhibition (%) | 1.9 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 10 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 10.1 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 10.6 | % |
CHO cells
|
Normal
|
||
| Cellular activity | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 100 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 100 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 11 | % |
Lymphocyte cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 11.78 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 12 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 127.1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 14.38 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Cellular activity | 14.38 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Cellular activity | 140.3 | pM of drug (10e6*cells)-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 15 | % |
CHO cells
|
Normal
|
||
| Cellular activity | 15.18 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 15.18 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cell-based Percent Inhibition (%) | 15.44 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 16 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 16.13 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Cellular activity | 16.13 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Cellular activity | 16.27 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 16.27 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 163.3 | pM of drug (10e6*cells)-1 |
J774.2 cells
|
Mouse reticulum cell sarcoma
|
||
| Cellular activity | 17 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 17 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 2.15 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 2.15 | % |
Vero C1008 cells
|
Normal
|
||
| Median Effective Dose (ED50) | 2.4 | ug ml-1 |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | ug.mL-1 |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | ug.mL-1 |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | ug.mL-1 |
WRL68 cells
|
Embryonic hepatoma
|
||
| Median Effective Dose (ED50) | 2.6 | ug ml-1 |
KB-V1 cells
|
Cervical carcinoma
|
||
| Median Effective Dose (ED50) | 2.6 | ug ml-1 |
KB-V1 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | ug.mL-1 |
WRL68 cells
|
Embryonic hepatoma
|
||
| Cell-based Percent Inhibition (%) | 2.76 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 2.76 | % |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.8 | ug.mL-1 |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Median Effective Dose (ED50) | >20 | ug ml-1 |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Median Effective Dose (ED50) | >20 | ug ml-1 |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Median Effective Dose (ED50) | >20 | ug ml-1 |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Median Effective Dose (ED50) | >20 | ug ml-1 |
HEp-2 cells
|
Laryngeal carcinoma
|
||
| Cellular activity | 200 | % | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >200 | ug.mL-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 200 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 21 | % |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Cellular activity | 21.68 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 21.68 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 24.25 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Cellular activity | 24.25 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Tumor Growth Inhibition (TGI) | <25 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | <25 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 25 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 26 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 28.2 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 28.2 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 29 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 29.6 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 29.6 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 3 | % |
CHO cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.6 | ug.mL-1 |
B16 cells
|
Melanoma
|
||
| Cellular activity | 30 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 30 | % |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Cellular activity | 30 | % |
A549 cells
|
Lung adenocarcinoma
|
||
| Cellular activity | 31 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 31 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 31.3 | pM of drug (10e6*cells)-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 33 | % |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Cellular activity | 33 | nM/mg*min | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 33 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 33.96 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 35 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 37 | % |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Cell-based Percent Inhibition (%) | 37 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 38.06 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 38.06 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3900 | ug.mL-1 |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | ug.mL-1 |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | ug.mL-1 |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | ug.mL-1 |
HepG2 cells
|
Hepatoblastoma
|
||
| Cellular activity | 40 | % |
CHO cells
|
Normal
|
||
| Cellular activity | 42 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 44 | % |
CEM-VLB cells
|
Vinblastine-resistant T-cell leukemia
|
||
| Cellular activity | 44 | % |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 45 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 45.13 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Cellular activity | 45.13 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Cellular activity | 47.54 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 47.54 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 48.75 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 48.75 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 49 | % |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Cellular activity | 49 | % |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Cellular activity | 49 | % |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Cellular activity | 5.3 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 50 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 50 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 50 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 50 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 50 | % | Undisclosed | Undisclosed | Undisclosed | |
| Tumor Growth Inhibition (TGI) | 51 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 51.5 | % |
MRC5 cells
|
Normal
|
||
| Cellular activity | 52.89 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 53 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 53.42 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 53.42 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 54 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 54.3 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 55 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Cellular activity | 55 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Cell-based Percent Inhibition (%) | 57.6 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 6.06 | % |
Lymphocyte cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6.1 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.1 | ug.mL-1 |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 6.6 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 60.06 | % |
MRC5 cells
|
Normal
|
||
| Cellular activity | 60.35 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 60.35 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 600 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 64 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 64.1 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 66 | % |
U-266 cells
|
Plasma cell myeloma
|
||
| Cell-based Percent Inhibition (%) | 66 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 69.7 | pM of drug (10e6*cells)-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 7.82 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 7.82 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | >70 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 72 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 72.13 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Cellular activity | 72.13 | % |
HepG2 cells
|
Hepatoblastoma
|
||
| Cell-based Percent Inhibition (%) | 73.93 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 75 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cellular activity | 75 | % |
P388/S cells
|
Leukemia
|
||
| Cellular activity | 75 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Tumor Growth Inhibition (TGI) | 76 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 76.24 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 76.24 | % |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 78 | % |
Sf9 cells
|
Normal
|
||
| Cellular activity | 80 | % |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | >80 | % |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 81 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 81.5 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 83.3 | % |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Cellular activity | 84.8 | pM of drug (10e6*cells)-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 87 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 9 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 9 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 90.9 | pM of drug (10e6*cells)-1 |
J774.2 cells
|
Mouse reticulum cell sarcoma
|
||
| Cellular activity | 92 | % |
P388/S cells
|
Leukemia
|
||
| Cellular activity | 96 | % |
P388/S cells
|
Leukemia
|
||
| Cellular activity | 25 | pM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.003 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.02 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.036 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.039 | nM |
SK-OV-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.039 | nM |
SK-OV-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.063 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.063 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.07 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.099 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.099 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.099 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.099 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.11 | nM |
KB 3-1 cells
|
Cervical epithelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.12 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.12 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.16 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.16 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Tumor Growth Inhibition (TGI) | <0.25 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <0.25 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <0.25 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Tumor Growth Inhibition (TGI) | <0.25 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.25 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Tumor Growth Inhibition (TGI) | 0.25 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <0.25 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Tumor Growth Inhibition (TGI) | 0.25 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Tumor Growth Inhibition (TGI) | <0.25 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.26 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.27 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.29 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.3 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.31 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.32 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.34 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.36 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.36 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.36 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.38 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.38 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.4 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.4 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.4 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.4 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.42 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.49 | nM |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.49 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.49 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.49 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.5 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 0.5 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.5 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.5 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.5 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.5 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.52 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.53 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.54 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.6 | nM |
SF539 cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.6 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.608 | nM |
JAR cells
|
Gestational choriocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.63 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.6303 | nM |
HCC1806 cells
|
Breast acantholytic squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.6975 | nM |
KOSC-2 cells
|
Floor of mouth squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.73 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.73 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.73 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.73 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.7882 | nM |
J-RT3-T3-5 cells
|
T acute lymphoblastic leukemi
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.79 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Tumor Growth Inhibition (TGI) | 0.8 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8 | nM |
J774.2 cells
|
Mouse reticulum cell sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8 | nM |
HUVEC cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.8 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.8 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.83 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.88 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Effective Concentration (EC50) | 0.9 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.9 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 0.9 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Activity Concentration (AC50) | 0.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.91 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.93 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.93 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.951 | nM |
5637 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Effective Concentration (EC50) | 1 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
U-87MG ATCC cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
U-87MG ATCC cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
U-87MG ATCC cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 1 | nM |
RXF 393 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
SNU-C1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
NIH3T3 cells
|
Normal
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.012 | nM |
HGC-27 cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.013 | nM |
ChaGo-K-1 cells
|
Bronchogenic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.03 | nM |
CAL-27 cells
|
Tongue adenosquamous carcinom
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.034 | nM |
ATN-1 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.05 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.05 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.1 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.1 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.1 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.11 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.11 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.126 | nM |
Becker cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.187 | nM |
IST-SL1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 1.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.211 | nM |
SF539 cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.218 | nM |
A2058 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.24 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.248 | nM |
PSN1 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.261 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.273 | nM |
NKM-1 cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.3 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.3 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1.37 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.38 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.405 | nM |
CTV-1 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.41 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.41 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.416 | nM |
BE-13 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.42 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.42 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.431 | nM |
NCI-H1703 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.439 | nM |
RXF 393 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.493 | nM |
MHH-PREB-1 cells
|
B-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.5 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.5 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1.5 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.5 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.502 | nM |
LCLC-103H cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.505 | nM |
SK-NEP-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.546 | nM |
Ramos-2G6-4C10 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.6 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Tumor Growth Inhibition (TGI) | 1.6 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1.6 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.6 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.6 | nM |
MES-SA cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.6 | nM |
H69AR cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.6 | nM |
NCI-H69 cells
|
Lung small cell carcinoma, Small cell lung cancer
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.622 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.636 | nM |
CTB-1 cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.658 | nM |
RPMI-7951 cells
|
Malignant melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.662 | nM |
MDA-MB-361 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.687 | nM |
DB cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.7 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.704 | nM |
P12-Ichikawa cells
|
T-cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.705 | nM |
JVM-3 cells
|
B-cell prolymphocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.756 | nM |
HO-1-N-1 cells
|
Buccal mucosa squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.793 | nM |
KARPAS-45 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.8 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.8 | nM |
P388D1 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.8 | nM |
P388D1 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.809 | nM |
DOHH2 cells
|
Diffuse large B-cell lymphoma germinal center B-cell type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.82 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.82 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.82 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.867 | nM |
A4-Fuk cells
|
B acute lymphoblastic leukemia
|
||
| Tumor Growth Inhibition (TGI) | 1.91 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.92 | nM |
GT3TKB cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.966 | nM |
RPMI-8866 cells
|
Chronic myelogenous leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 10 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <10 | nM |
Jurkat cells
|
Childhood T acute lymphoblastic leukemia, Precursor T-cell acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <10 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <10 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <10 | nM |
DLD-1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <10 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <10 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <10 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Tumor Growth Inhibition (TGI) | <10 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <10 | nM |
SF268 cells
|
Astrocytoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | <10 | nM |
SF268 cells
|
Astrocytoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 10 | nM |
M21 cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 10 | nM |
M21 cells
|
Melanoma
|
||
| Half Maximal Activity Concentration (AC50) | 10 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 10 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.05 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.06 | nM |
NCI-H1048 cells
|
Lung small cell carcinoma, Small cell lung cancer
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.1 | nM |
CAL-62 cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.1 | nM |
MKN-1 cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.12 | nM |
LB2241-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.16 | nM |
WM-115 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.29 | nM |
LXF-289 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.3 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.38 | nM |
HTC-C3 cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.6 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10.66 | nM |
SCC-9 cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.78 | nM |
EPLC-272H cells
|
Lung mucoepidermoid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.8 | nM |
U-266 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.81 | nM |
EGI-1 cells
|
Cholangiocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10.85 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10.9 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | >100 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | >100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | <100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 100 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >1000 | nM |
IMR-90 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 1000 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 10000 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 101.3 | nM |
SW684 cells
|
Fibrosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 101.38 | nM |
CW-2 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1040 | nM |
KB-V1 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10471.29 | nM |
A2780 ADR cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1082.28 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 109.77 | nM |
SiHa cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 11.07 | nM |
P30-OHK cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.08 | nM |
MZ7-mel cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.25 | nM |
SNB-75 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.28 | nM |
GMS-10 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.35 | nM |
HEC-1 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.4 | nM |
T98G cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.42 | nM |
SNU-387 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.75 | nM |
SK-UT-1 cells
|
Uterine corpus leiomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11.9 | nM |
TYK-nu cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >110 | nM |
HCT-116/VM46 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >=110 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >110 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1100 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 11180 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Activity Concentration (AC50) | 1122 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 1122 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1128.93 | nM |
RH-18 cells
|
Alveolar rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1130 | nM |
BXPC-3 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 114.18 | nM |
Capan-2 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 114700 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 115.12 | nM |
ES6 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 115.72 | nM |
Lu-65 cells
|
Lung giant cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1150 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 116.58 | nM |
RMG-I cells
|
Ovarian clear cell adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1163.6 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 119.71 | nM |
A704 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
CHL-1 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.05 | nM |
SK-HEP-1 cells
|
Liver and intrahepatic bile duct epithelial neoplasm
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.06 | nM |
SJSA-1 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.22 | nM |
MSTO-211H cells
|
Pleural biphasic mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.28 | nM |
HUTU 80 cells
|
Duodenal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.3 | nM |
AGS cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.4 | nM |
LN-405 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.48 | nM |
JEG-3 cells
|
Gestational choriocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.55 | nM |
A-427 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.56 | nM |
BB49-HNC cells
|
Floor of mouth squamous cell carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 12.6 | nM |
KB 3-1 cells
|
Cervical epithelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.64 | nM |
HuO9 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 12.66 | nM |
C-33-A cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 120.44 | nM |
SW837 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 121.72 | nM |
HCC1954 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Activity Concentration (AC50) | 121.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 126.77 | nM |
NCI-H1650 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 127.72 | nM |
SNU-449 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 129 | nM |
DLD-1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 13 | nM |
KB-V1 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.12 | nM |
CP50-MEL-B cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.15 | nM |
NCI-H209 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.21 | nM |
ASPC1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.6 | nM |
OVCAR-5 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.81 | nM |
NCI-H226 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.83 | nM |
ES4 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13.94 | nM |
UO-31 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 130 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1300 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 132.84 | nM |
SNU-5 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 133.77 | nM |
NCI-H1304 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >133000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >133000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >133000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 135 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 135.12 | nM |
NCI-H2347 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 135.5 | nM |
MFM-223 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >135000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 136.2 | nM |
COLO-824 cells
|
Breast carcinoma
|
||
| Half Maximal Activity Concentration (AC50) | 136.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 136.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1369.69 | nM |
RCM-1 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 138.49 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 14 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.08 | nM |
LU-139 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.16 | nM |
MG-63 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.42 | nM |
KM12 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.7 | nM |
SW756 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.74 | nM |
MEG-01 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14.77 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 1402 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1406.87 | nM |
HOP-62 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1410 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 144 | nM |
MES-SA/Dx5 cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 144 | nM |
MES-SA/Dx5 cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 144 | nM |
MES-SA/Dx5 cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 144.1 | nM |
OMC-1 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 145.03 | nM |
LB2518-MEL cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 14500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 14600 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 148.18 | nM |
SHP-77 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 149.1 | nM |
Calu-6 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.06 | nM |
M059J cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.09 | nM |
MMAC-SF cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.15 | nM |
RERF-LC-MS cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.33 | nM |
BHY cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.49 | nM |
ABC-1 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.58 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.64 | nM |
HT cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.68 | nM |
SCC-25 cells
|
Squamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.7 | nM |
NB5 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.73 | nM |
A2780S cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.83 | nM |
TGBC11TKB cells
|
Gastric carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15.9 | nM |
J774.2 cells
|
Mouse reticulum cell sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 15000 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 156.07 | nM |
NCI-H596 cells
|
Lung adenosquamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 15980 | nM |
HEL cells
|
Erythroleukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.06 | nM |
SN12C cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.19 | nM |
SF268 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.39 | nM |
CAL-51 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.42 | nM |
NCI-H1299 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.52 | nM |
DoTc2-4510 cells
|
Cervix uteri
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.79 | nM |
KU812 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.88 | nM |
C2BBe1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 16.97 | nM |
SW1088 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 160 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Effective Concentration (EC50) | 160 | nM |
DLD-1 cells
|
Colon adenocarcinoma
|
||
| Tumor Growth Inhibition (TGI) | 1600 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Tumor Growth Inhibition (TGI) | 1600 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 162 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1630 | nM |
MCF7-VP cells
|
Breast carcinoma
|
||
| Tumor Growth Inhibition (TGI) | 1640 | nM |
SF268 cells
|
Astrocytoma
|
||
| Tumor Growth Inhibition (TGI) | 1640 | nM |
SF268 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1642.17 | nM |
NCI-H82 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1650 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1657.4 | nM |
KARPAS-299 cells
|
ALK-positive anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1660 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 16890.22 | nM |
A2780/Taxol cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17 | nM |
CHO cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 17 | nM |
CHO cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.04 | nM |
SK-MEL-28 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.24 | nM |
SKG-IIIa cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.29 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 17.31 | nM |
Hs578T cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.51 | nM |
MEL-JUSO cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.58 | nM |
G-402 cells
|
Kidney neoplasm
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17.96 | nM |
HuP-T3 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 170 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1740 | nM |
SK-MEL-5 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 175.7 | nM |
NCI-H727 cells
|
Lung carcinoid tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17700 | nM |
NIH-3T3-G185 cells
|
Nornal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 17740 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 18.01 | nM |
EW-24 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.09 | nM |
HCE-4 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.38 | nM |
KG-1 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.55 | nM |
MDA-MB-415 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.69 | nM |
KNS-42 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.71 | nM |
SK-LU-1 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 18.86 | nM |
D-392MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1870 | nM |
Platelet cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 19 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.17 | nM |
COLO-829 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.27 | nM |
VMRC-RCZ cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.36 | nM |
NCI-H1755 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.38 | nM |
GAMG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.39 | nM |
SW 962 cells
|
Vulva lymphoid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.47 | nM |
SNU-423 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.51 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.54 | nM |
NCI-H1355 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.6 | nM |
LS174T cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19.83 | nM |
HCC 2998 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1900 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 191.13 | nM |
NCI-H1838 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 193 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 193000 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 195.12 | nM |
NB7 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 19900 | nM |
NIH-3T3-G185 cells
|
Nornal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 2 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
MX1 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
HCT-116/VM46 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.043 | nM |
D-566MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.076 | nM |
IGR-1 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.086 | nM |
CAL-27 cells
|
Tongue adenosquamous carcinom
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.1 | nM |
J774 cells
|
Mouse reticulum cell sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.122 | nM |
NCI-H446 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.139 | nM |
COLO-741 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.16 | nM |
DEL cells
|
Anaplastic large cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM |
MX1 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM |
MX1 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.225 | nM |
OC-314 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.248 | nM |
H9 cells
|
Sezary syndrome
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.28 | nM |
MES-SA cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.28 | nM |
MES-SA cells
|
Uterine sarcoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2.3 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Cellular activity | 2.3 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.329 | nM |
SW780 cells
|
Mouse melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.33 | nM |
BCPAP cells
|
Thyroid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.355 | nM |
HSC-4 cells
|
Cervical lymph node
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.369 | nM |
KP-4 cells
|
Pancreatic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.395 | nM |
SCC-4 cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.4 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.429 | nM |
MOLT-16 cells
|
T acute lymphoblastic leukemia
|
||
| Tumor Growth Inhibition (TGI) | 2.5 | nM |
SF539 cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.698 | nM |
MKN-28 cells
|
Gastric epithelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.7 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.7 | nM |
SK-OV-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.708 | nM |
RT-112 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.753 | nM |
NCI-H510A cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.754 | nM |
HCC1187 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.766 | nM |
ES3 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.8 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.8 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2.8 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.8 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.805 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.852 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.9 | nM |
KPL4 cells
|
Breast inflammatory carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.9 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.9 | nM |
MX1 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.9 | nM |
MX1 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.9 | nM |
MX1 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.985 | nM |
MC-IXC cells
|
Askin tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
LS174T cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.01 | nM |
HCE-T cells
|
Nornal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.02 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.12 | nM |
NCI-H1666 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.16 | nM |
KNS-81-FD cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.2 | nM |
HSC-2 cells
|
Oral cavity squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.2 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.64 | nM |
23132-87 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.7 | nM |
BB65-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.76 | nM |
KMOE-2 cells
|
Erythroleukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.8 | nM |
HCC70 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.83 | nM |
LU-99A cells
|
Lung giant cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.94 | nM |
DMS 114 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 200 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 200 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 20000 | nM |
C2C12 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20000 | nM |
SNU-C1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 203.7 | nM |
NCI-H2029 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 203.92 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 2037 | nM |
KB-V1 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2049.18 | nM |
HCC1937 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 205 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 205 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 2051 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 2051000 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2059 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 206.6 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 21 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21.16 | nM |
ECC10 cells
|
Gastric small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21.23 | nM |
LB831-BLC cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21.46 | nM |
NCI-H1563 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21.47 | nM |
TE-10 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21.77 | nM |
NB17 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21.9 | nM |
SF-126 cells
|
Glioblastoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 210 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 21000 | nM |
MDCK cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 211 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 215.27 | nM |
IGROV-1 cells
|
Endometrioid carcinoma of ovary, Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 219.86 | nM |
GAK cells
|
Vulvar melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22.5 | nM |
A2780S cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22.91 | nM |
KP-N-YS cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 223.56 | nM |
NCI-H1092 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 225.99 | nM |
DBTRG-05MG cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 22700 | nM |
ACHN cells
|
Renal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23 | nM |
NCI-H1651 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.03 | nM |
647-V cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.15 | nM |
SCC-15 cells
|
Squamous cell carcinoma of the oral tongue, Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.21 | nM |
SW626 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.21 | nM |
DSH1 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.49 | nM |
D-502MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.53 | nM |
A-375 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 23.63 | nM |
TCCSUP cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 230 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 230 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 230 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 232.1 | nM |
NCI-H2291 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 233.07 | nM |
KURAMOCHI cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 233.12 | nM |
OAW-42 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 233.41 | nM |
HAL-01 cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2360 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24 | nM |
MRC5 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24.19 | nM |
MZ1-PC cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24.23 | nM |
NCI-H1975 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24.32 | nM |
COR-L88 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24.61 | nM |
CAKI-1 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24.65 | nM |
NCI-H2052 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24.67 | nM |
SNU-C2B cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 24080 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 241.69 | nM |
NCI-H630 cells
|
Colon carcinoma
|
||
| Tumor Growth Inhibition (TGI) | 2440 | nM |
DLD-1 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 246 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 248.27 | nM |
A549/TR cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2480 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2480.78 | nM |
COLO-678 cells
|
Colon carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 25 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25 | nM |
ACHN cells
|
Renal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25.41 | nM |
SW900 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25.55 | nM |
769-P cells
|
Renal cell carcinom
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25.63 | nM |
COLO-792 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25.72 | nM |
U2OS cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25.9 | nM |
NCI-H2126 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25.92 | nM |
HOP-92 cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2511.89 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2511.89 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 25118.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 25191 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 255.22 | nM |
SW872 cells
|
Liposarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 255.94 | nM |
H-EMC-SS cells
|
Extraskeletal myxoid chondrosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 25860 | nM |
MCF-10A cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 26 | nM |
SNU-398 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 26 | nM |
SNU-398 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26.35 | nM |
NH-12 cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26.61 | nM |
RPMI-2650 cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 260 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Activity Concentration (AC50) | <260 | nM |
RMG-I cells
|
Ovarian clear cell adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 26000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 267.63 | nM |
MDA-MB-175-VII cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Activity Concentration (AC50) | 26870.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 27 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.01 | nM |
C8166 cells
|
Leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.08 | nM |
NCI-H650 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.5 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.72 | nM |
NCI-H2030 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27.94 | nM |
OVCAR-4 cells
|
Ovarian adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 270.54 | nM |
no-10 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 27060 | nM |
Vero cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 278.22 | nM |
EKVX cells
|
Non-small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Effective Concentration (EC50) | 28 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 28.13 | nM |
SAS cells
|
Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28.46 | nM |
NCI-H1770 cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28.5 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28.5 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28.59 | nM |
OE33 cells
|
Barrett adenocarcinoma, Adenocarcinoma of the esophagus
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28.7 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2816.86 | nM |
DJM-1 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2818.38 | nM |
A2780 ADR cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2844 | nM |
LS1034 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 285 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29.25 | nM |
HCC1395 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29.35 | nM |
EW-22 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29.44 | nM |
MN-60 cells
|
Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29.6 | nM |
NCI-H1793 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29.72 | nM |
SCH cells
|
Gastric choriocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29.98 | nM |
U-87MG ATCC cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29000 | nM |
MDCK cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29300 | nM |
LNCaP cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 29500 | nM |
NIH-3T3-G185 cells
|
Nornal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 3 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
MES-SA cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
MES-SA cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
MES-SA cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
MCF7-VP cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
MCF7-VP cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.03 | nM |
NCI-H292 cells
|
Lung mucoepidermoid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.102 | nM |
Daoy cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.109 | nM |
8505C cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.148 | nM |
EW-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.15 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.191 | nM |
M14 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.2 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.2 | nM |
LNCaP cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.2 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.212 | nM |
TI-73 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.232 | nM |
NBsusSR cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.24 | nM |
ES8 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.263 | nM |
BPH-1 cells
|
Benign prostatic hyperplasia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.273 | nM |
VA-ES-BJ cells
|
Epithelioid sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.274 | nM |
NB13 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.285 | nM |
MDA-MB-453 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.3 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.319 | nM |
HT-144 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.33 | nM |
HD-MY-Z cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.342 | nM |
COLO-800 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.388 | nM |
MIA PaCa-2 cells
|
Pancreatic undifferentiated carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.396 | nM |
DMS-273 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.4 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.4 | nM |
RH-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.436 | nM |
NCI-H2122 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.448 | nM |
AU565 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.455 | nM |
NUGC-3 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.5 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.5 | nM |
HCC70 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.5 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.5 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.5 | nM |
C2C12 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.531 | nM |
EC-GI-10 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.534 | nM |
PC-14 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.547 | nM |
CHP-212 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.623 | nM |
COR-L23 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.626 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.67 | nM |
8305C cells
|
Thyroid gland anaplastic carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.69 | nM |
KY821 cells
|
Acute myelomonocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.7 | nM |
A2058 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.7 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.702 | nM |
YH-13 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.742 | nM |
ONS-76 cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.773 | nM |
BFTC-905 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.8 | nM |
BPH-1 cells
|
Benign prostatic hyperplasia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.8 | nM |
HCC1143 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.847 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.882 | nM |
ES5 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.9 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.905 | nM |
HMV-2 cells
|
Vaginal melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3.993 | nM |
KE-37 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30.13 | nM |
NCI-H520 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30.28 | nM |
MPP-89 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30.53 | nM |
NCI-H2087 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30.74 | nM |
NCI-H1573 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30.83 | nM |
MS-1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 300 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 300 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3000 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3000 | nM |
C32 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30000 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 309.15 | nM |
L-428 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 309.24 | nM |
KLE cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31.21 | nM |
TGBC1TKB cells
|
Gallbladder undifferentiated carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31.36 | nM |
BHT-101 cells
|
Anaplastic thyroid carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31.39 | nM |
A101D cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31.55 | nM |
SK-MEL-24 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31.6 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 313.17 | nM |
BALL-1 cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31520 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 31640 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3184 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 32 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Effective Concentration (EC50) | 32 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Effective Concentration (EC50) | 32 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 32 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 32.01 | nM |
CAMA-1 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 32.31 | nM |
SAOS-2 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 32.5 | nM |
SW480 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 32.52 | nM |
TGBC24TKB cells
|
Gallbladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 32.84 | nM |
HEL cells
|
Erythroleukemia
|
||
| Tumor Growth Inhibition (TGI) | 320 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 33.25 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 33.33 | nM |
KGN cells
|
Ovarian granulosa cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 33.37 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 33.41 | nM |
NCI-H2170 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 332.14 | nM |
C3A cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3395.38 | nM |
NCI-H1993 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 34.26 | nM |
NCI-H28 cells
|
Pleural mesothelioma
|
||
| Half Maximal Effective Concentration (EC50) | 34000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 34000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 35 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 35.58 | nM |
LU-135 cells
|
Lung small cell carcinoma
|
||
| Tumor Growth Inhibition (TGI) | 350 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Tumor Growth Inhibition (TGI) | 350 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 350 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 35100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 356 | nM |
CEM/VLB100 cells
|
Acute lymphoblastic leukemia
|
||
| Half Maximal Effective Concentration (EC50) | 36 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 36 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 36.08 | nM |
MFE-280 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 36.31 | nM |
SF-295 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 36.52 | nM |
EW-13 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 36.92 | nM |
AM-38 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 37 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 37.01 | nM |
NCI-H358 cells
|
Minimally invasive lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 37.07 | nM |
HT-3 cells
|
Cervical carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 37.21 | nM |
EW-3 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 37.37 | nM |
SK-N-DZ cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 37.68 | nM |
BT-20 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 37.8 | nM |
SK-HEP1 cells
|
Liver and intrahepatic bile duct epithelial neoplasm
|
||
| Half Maximal Effective Concentration (EC50) | <3700 | nM |
Vero cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 37490 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | >375 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >375000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 37600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 38 | nM |
SNU-398 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 38.83 | nM |
no-11 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 38.85 | nM |
MHH-NB-11 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 383.01 | nM |
DU-4475 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 3876.68 | nM |
D-542MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 39.1 | nM |
D283 Med cells
|
Medulloblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 39.85 | nM |
GB-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 391.6 | nM |
HT55 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 392.48 | nM |
CEM-VLB cells
|
Vinblastine-resistant T-cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 392.5 | nM |
CEM-VLB cells
|
Vinblastine-resistant T-cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 392480 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 398.11 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 398.11 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 398.11 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 39810.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
AU565 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 4 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
A2058 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
A2058 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
N592 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.1 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.1 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 4.1 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.15 | nM |
HN cells
|
Cervical lymph node
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.172 | nM |
RD cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.196 | nM |
DOK cells
|
Oral epithelial dysplasia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4.2 | nM |
WPMY-1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.211 | nM |
HC-1 cells
|
Hairy cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.228 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4.235 | nM |
HLE cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.236 | nM |
NCI-H1581 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.27 | nM |
TE-9 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.277 | nM |
NCI-H1395 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.281 | nM |
VM-CUB-1 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.3 | nM |
P388/ADR cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.32 | nM |
A3-KAW cells
|
Diffuse large B-cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.362 | nM |
GI-1 cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.371 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.389 | nM |
HSC-3 cells
|
Oral squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.391 | nM |
NCI-H1792 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.4 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.4 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.4 | nM |
MDA-MB-435 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.473 | nM |
ME-180 cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.48 | nM |
FaDu cells
|
Hypopharyngeal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.5 | nM |
786-O cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.5 | nM |
NCI-H520 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.5 | nM |
NCI-H520 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.5 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.508 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4.52 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.526 | nM |
IST-MEL1 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | nM |
MDA-MB-468 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | nM |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.6 | nM |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.608 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.652 | nM |
MLMA cells
|
Hairy cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.674 | nM |
GP5d cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.682 | nM |
K5 cells
|
Thyroid gland papillary carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.694 | nM |
Ca-Ski cells
|
Cervical squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.714 | nM |
ES1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.728 | nM |
GCT cells
|
Pleomorphic sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.8 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.827 | nM |
HuO-3N1 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.83 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.876 | nM |
ESS-1 cells
|
Endometrioid stromal sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.953 | nM |
NB14 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.954 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4.972 | nM |
PFSK-1 cells
|
Primitive neuroectodermal tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40.05 | nM |
HPAF-II cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40.27 | nM |
LB1047-RCC cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40.29 | nM |
ACN cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40.72 | nM |
OAW-28 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 40.88 | nM |
NOS-1 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >40000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >40000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 402.55 | nM |
ZR-75-30 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 41.09 | nM |
NCI-H2228 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 410 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 412.2 | nM |
OE19 cells
|
Esophageal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4123.67 | nM |
G-361 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 415.46 | nM |
SK-MEL-30 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 42.27 | nM |
BV-173 cells
|
Chronic myelogenous leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 42.4 | nM |
TK-10 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 42.5 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 42.8 | nM |
Panc1005 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 423.54 | nM |
SW1417 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4250 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4280 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 43 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 43 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 43.18 | nM |
HuP-T4 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 43.54 | nM |
SH-4 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 43.72 | nM |
KU-19-19 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 43.74 | nM |
NCI-H1155 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 43500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 439.73 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 439.73 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 44 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 44 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 44.03 | nM |
EFO-21 cells
|
Ovarian serous cystadenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 44.59 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 44.94 | nM |
KYSE-140 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 440 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 45.16 | nM |
U-118-MG cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 45.73 | nM |
CaR-1 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 45.85 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 45500 | nM |
COR-L23 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 45600 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4580 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 46.36 | nM |
KP-N-YN cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 46.39 | nM |
NCI-H460 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 46.53 | nM |
KYSE-150 cells
|
Esophageal squamous cell carcinoma, Squamous cell carcinoma of the esophagus
|
||
| Half Maximal Inhibitory Concentration (IC50) | 46.86 | nM |
OVCAR-3 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 46800 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 47.62 | nM |
KYSE-520 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 47.7 | nM |
LAN-6 cells
|
Neuroblastoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 470 | nM |
P388/ADR cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 473.3 | nM |
NCI-H441 cells
|
Lung papillary adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 48 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 48.35 | nM |
KYSE-70 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 48.42 | nM |
MKN-45 cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 48.58 | nM |
CP66-MEL cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 480 | nM |
K-562R cells
|
Leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 49 | nM |
HUVEC cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 49.73 | nM |
GCIY cells
|
Gastric adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4900 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 496 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 496 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 496 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 4975.15 | nM |
A-431 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
SCLC cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Growth Inhibitory Concentration (GI50) | 5 | nM |
SNU-398 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 5 | nM |
SNU-398 cells
|
Hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.018 | nM |
U251 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.1 | nM |
LNCaP cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.1 | nM |
LNCaP-Clone-FGC cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.104 | nM |
T24 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.107 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5.114 | nM |
CAL-39 cells
|
Vulvar squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.122 | nM |
NEC8 cells
|
Testicular embryonal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.128 | nM |
TE-11 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.129 | nM |
MHH-ES-1 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.136 | nM |
NCI-H526 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 5.2 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5.21 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.215 | nM |
ALL-PO cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.242 | nM |
EFM-19 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.316 | nM |
EM-2 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.339 | nM |
KM-H2 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.472 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5.49 | nM |
SW13 cells
|
Adrenal cortex carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.491 | nM |
LCLC-97TM1 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.5 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.519 | nM |
NCI-H1648 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.531 | nM |
Detroit 562 cells
|
Pharyngeal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.534 | nM |
YKG-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.556 | nM |
CGTH-W-1 cells
|
Thyroid gland squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.57 | nM |
RO82-W-1 cells
|
Thyroid gland follicular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.576 | nM |
S-117 cells
|
Thyroid gland sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.603 | nM |
MOLT-13 cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.605 | nM |
639-V cells
|
Ureter urothelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.607 | nM |
SW1710 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.671 | nM |
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.706 | nM |
NCI-H23 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.73 | nM |
NB69 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.753 | nM |
ES7 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.788 | nM |
ETK-1 cells
|
Cholangiocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.8 | nM |
C2C12 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.802 | nM |
KNS-62 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.837 | nM |
H4 cells
|
Neuroglioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.875 | nM |
KYSE-510 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.893 | nM |
NTERA-2-cl-D1 cells
|
Teratocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.938 | nM |
A498 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.997 | nM |
L-363 cells
|
Plasma cell myeloma
|
||
| Tumor Growth Inhibition (TGI) | 50 | nM |
RXF 393 cells
|
Renal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 50 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Effective Concentration (EC50) | 500 | nM |
LNCaP cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 500 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 5000 | nM |
MES-SA/Dx5 cells
|
Uterine sarcoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 5000 | nM |
MES-SA/Dx5 cells
|
Uterine sarcoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 5000 | nM |
MES-SA/Dx5 cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >50000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5011.87 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 503.24 | nM |
NCI-H1623 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5037 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 510.36 | nM |
EW-18 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 510.4 | nM |
RCC10RGB cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 52.3 | nM |
CAPAN-1 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 52.5 | nM |
RD cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5205 | nM |
HCT-8 cells
|
Ileocecal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 525.78 | nM |
NCI-H69 cells
|
Lung small cell carcinoma, Small cell lung cancer
|
||
| Half Maximal Inhibitory Concentration (IC50) | 53 | nM |
RD cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 53 | nM |
RD cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 53.3 | nM |
SK-MEL-2 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 53.33 | nM |
LS-123 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 53.45 | nM |
NCI-H2009 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 53.86 | nM |
MEL-HO cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5315.23 | nM |
NY cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 534.65 | nM |
DMS-79 cells
|
Small cell lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 54.7 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 540 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5415.81 | nM |
COLO-679 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 55.97 | nM |
CAL-12T cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 550 | nM |
HT-29 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 551 | nM |
Calu-3 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5585.18 | nM |
JVM-2 cells
|
Mantle cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 56 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 56.27 | nM |
LS-513 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 56.47 | nM |
TE-6 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 562.6 | nM |
COLO-668 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 57.16 | nM |
HCC1419 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 58.38 | nM |
HCC38 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 58.6 | nM |
SK-LMS-1 cells
|
Vulvar leiomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 582 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5846 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 588.37 | nM |
MFH-ino cells
|
Pleomorphic sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 59.04 | nM |
ACHN cells
|
Renal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 59.36 | nM |
SJRH30 cells
|
Alveolar rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5946000 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 6 | nM |
MES-SA cells
|
Uterine sarcoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 6 | nM |
MES-SA cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6 | nM |
L1210 cells
|
Lymphoblastic leukemia
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 6 | nM |
MES-SA cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.025 | nM |
LoVo cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.076 | nM |
GI-ME-N cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.135 | nM |
TE-5 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.138 | nM |
SK-PN-DW cells
|
Primitive neuroectodermal tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.156 | nM |
TE-8 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.184 | nM |
CAL-33 cells
|
Squamous cell carcinoma of the oral tongue, Tongue squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.225 | nM |
697 cells
|
Childhood B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.25 | nM |
HOS cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.335 | nM |
8-MG-BA cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.367 | nM |
HH cells
|
T-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.385 | nM |
KYSE-180 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.391 | nM |
Ca9-22 cells
|
Gingival squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.554 | nM |
OVCAR-8 cells
|
High grade ovarian serous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.646 | nM |
DK-MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.8 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.875 | nM |
A673 cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.88 | nM |
NCI-H720 cells
|
Lung carcinoid tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.9 | nM |
CHO-TAX 5-6 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.9 | nM |
CHO-TAX 5-6 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.915 | nM |
A388 cells
|
Skin squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.943 | nM |
SW48 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.977 | nM |
LOX IMVI cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6.979 | nM |
D-247MG cells
|
Gliosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 60 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60.31 | nM |
MZ2-MEL cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60.4 | nM |
HT-1376 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 60.59 | nM |
CAL-54 cells
|
Renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
CEM-VLB cells
|
Vinblastine-resistant T-cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
CEM-VLB cells
|
Vinblastine-resistant T-cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HCT-116/VM46 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HCT-116/VM46 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HCT-116/VM46 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HCT-116/VM46 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HCT-116/VM46 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 600 | nM |
HCT-116/VM46 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6079.95 | nM |
CAL-85-1 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 61.39 | nM |
SW1990 cells
|
Pancreatic adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 61.41 | nM |
NB12 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 61.47 | nM |
PANC-08-13 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 61.66 | nM |
A2780 cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 62000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 623.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 64.11 | nM |
LB373-MEL-D cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 642.78 | nM |
SK-N-FI cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 642.79 | nM |
HDLM-2 cells
|
Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 647.18 | nM |
CAL-72 cells
|
Osteosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 65.75 | nM |
COR-L105 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 66 | nM |
CHO-VV 3-2 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 66 | nM |
CHO-VV 3-2 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 66.35 | nM |
LS-411N cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 67.32 | nM |
SK-MEL-1 cells
|
Metastatic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 67.68 | nM |
IST-MES1 cells
|
Pleural epithelioid mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 670 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 67300 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >67541 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >67541 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 68.47 | nM |
J82 cells
|
Bladder carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 68.58 | nM |
IA-LM cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 68.69 | nM |
NCI-H810 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 680 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 680 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 6880 | nM |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 6899 | nM |
A2780/Taxol cells
|
Ovarian endometrioid adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 69.69 | nM |
SW1463 cells
|
Rectal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 69.84 | nM |
OS-RC-2 cells
|
Clear cell renal cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 69000 | nM |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 7 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 7 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 7 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 7 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
HEp-2 cells
|
Laryngeal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.015 | nM |
LAMA-84 cells
|
Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.151 | nM |
EW-11 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.249 | nM |
RVH-421 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.255 | nM |
D-336MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.3 | nM |
MCF-7 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.317 | nM |
NB10 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.449 | nM |
EFO-27 cells
|
Ovarian mucinous adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.471 | nM |
SBC-5 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.503 | nM |
LK-2 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.532 | nM |
BFTC-909 cells
|
Renal pelvis urothelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.561 | nM |
OCUB-M cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.631 | nM |
GR-ST cells
|
B acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.666 | nM |
COLO-684 cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.7 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.711 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.76 | nM |
NCI-H1437 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.787 | nM |
KALS-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.8 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.832 | nM |
EW-16 cells
|
Ewing sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.859 | nM |
NOMO-1 cells
|
Acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.896 | nM |
LC-2-ad cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.9 | nM |
SW403 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.953 | nM |
MC116 cells
|
B-cell non-Hodgkin lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.977 | nM |
BT-549 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7.987 | nM |
KS-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 70 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 70.4 | nM |
NIH3T3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 700 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 700.72 | nM |
TE-12 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 717.01 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 72 | nM |
SK-BR-3 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 7200 | nM |
A-375 cells
|
Amelanotic melanoma
|
||
| Half Maximal Effective Concentration (EC50) | 73 | nM |
NCI-H1299 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 73.3 | nM |
SK-MEL-28 cells
|
Cutaneous melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 74.71 | nM |
COLO-680N cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 740 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 75.99 | nM |
SW948 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 76.22 | nM |
UMC-11 cells
|
Lung carcinoid tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 76.69 | nM |
MKN7 cells
|
Gastric tubular adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 766 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 766000 | nM |
PC-3 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 78 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 78 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 78 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 78 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 78.21 | nM |
NCI-H1693 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 78.58 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 79.26 | nM |
HCC2218 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 79.4 | nM |
HCT-15 cells
|
Colon adenocarcinoma
|
||
| Tumor Growth Inhibition (TGI) | 790 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 794.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7950 | nM |
Hepatocyte cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7950 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 8 | nM |
ZR-75-1 cells
|
Invasive breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8 | nM |
KB cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8 | nM |
CEM-VM1 cells
|
Etoposide-resistant T-cell leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.01 | nM |
BXPC-3 cells
|
Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.047 | nM |
NCI-H661 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.059 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 8.062 | nM |
UACC-62 cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.092 | nM |
PA-1 cells
|
Ovarian mixed germ cell tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.1 | nM |
U251 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.1 | nM |
U251 cells
|
Astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.104 | nM |
SBC-1 cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.2 | nM |
P388 cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.207 | nM |
GOTO cells
|
Adrenal gland neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.239 | nM |
RKO cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.279 | nM |
LNCaP-Clone-FGC cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.3 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.315 | nM |
BB30-HNC cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.444 | nM |
FTC-133 cells
|
Thyroid gland follicular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.484 | nM |
NMC-G1 cells
|
Astrocytoma
|
||
| Half Maximal Effective Concentration (EC50) | 8.5 | nM |
KB 3-1 cells
|
Cervical epithelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.574 | nM |
LB771-HNC cells
|
Head and neck squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.582 | nM |
LU-134-A cells
|
Lung small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.639 | nM |
D-423MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.645 | nM |
SK-MES-1 cells
|
Lung squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.652 | nM |
ML-2 cells
|
Acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.669 | nM |
SK-N-AS cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.671 | nM |
G-401 cells
|
Kidney Wilm's tumor
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.7 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.7 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.7 | nM |
HCT116 cells
|
Colon carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.765 | nM |
A204 cells
|
Rhabdomyosarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.78 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.78 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.78 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.8 | nM |
MDA-MB-231 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.836 | nM |
SW620 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.9 | nM |
MES-SA/Dx5 cells
|
Uterine sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.9 | nM |
C2C12 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.919 | nM |
SW982 cells
|
Biphasic synovial sarcoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8.95 | nM |
QIMR-WIL cells
|
Acute myeloid leukemia
|
||
| Half Maximal Effective Concentration (EC50) | <80 | nM |
T47D cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 80 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Effective Concentration (EC50) | <80 | nM |
COLO 320 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 80.02 | nM |
NB6 cells
|
Neuroblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 80.7 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 800 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8000 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 81 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 81 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 81.18 | nM |
NCI-H747 cells
|
Cecum adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 81.23 | nM |
BEN cells
|
Lung non-small cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8147.21 | nM |
T84 cells
|
Colon adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8155.03 | nM |
SK-OV-3 cells
|
Ovarian serous adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 82 | nM |
NCI-H1299 cells
|
Lung large cell carcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 8200 | nM |
C6 cells
|
Glioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 826.38 | nM |
NCI-H2405 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 85.55 | nM |
SW1783 cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 86.8 | nM |
LLC-PK1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 86.99 | nM |
YAPC cells
|
Pancreas carincoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 866.85 | nM |
C32 cells
|
Amelanotic melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 87.26 | nM |
CAL-120 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 87.74 | nM |
Huh-7 cells
|
Adult hepatocellular carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 870 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 880.24 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 891.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9.064 | nM |
MDA-MB-157 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.134 | nM |
MeWo cells
|
Melanoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.278 | nM |
D-263MG cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.297 | nM |
KYSE-410 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.3 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.324 | nM |
KINGS-1 cells
|
Anaplastic astrocytoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.4 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.4 | nM |
CCRF-CEM cells
|
T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.587 | nM |
NCI-H2452 cells
|
Pleural mesothelioma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.616 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9.632 | nM |
KYSE-270 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.649 | nM |
KYSE-450 cells
|
Esophageal squamous cell carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.662 | nM |
SW 954 cells
|
Vulva squamous carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.765 | nM |
AN3-CA cells
|
Endometrial adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9.815 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9.9 | nM |
A549 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 90 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 90.53 | nM |
UACC-257 cells
|
Melanoma
|
||
| Half Maximal Growth Inhibitory Concentration (GI50) | 900 | nM |
SW1573 cells
|
Lung carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 92.26 | nM |
HCC1569 cells
|
Breast ductal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9200 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 9251.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 9271000 | nM |
KB 3-1 cells
|
Cervical epithelial carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 93.12 | nM |
CAS-1 cells
|
Glioblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 93.2 | nM |
CFPAC-1 cells
|
Cystic fibrosis, Pancreatic ductal adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 94 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 94.15 | nM |
BT-474 cells
|
Invasive breast carcinoma of no special type
|
||
| Half Maximal Inhibitory Concentration (IC50) | 9490 | nM |
K562 cells
|
Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Chronic myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 95 | nM |
P388/ADR cells
|
Lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 950 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 950.45 | nM |
NCI-H2342 cells
|
Lung adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 96 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 98.3 | nM |
UACC-893 cells
|
Breast carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 98.66 | nM |
DU145 cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 99.76 | nM |
HT-1197 cells
|
Recurrent bladder carcinoma
|
||
| Half Maximal Activity Concentration (AC50) | 0.0008913 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.01 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1219 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1219 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1367 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1367 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1534 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 0.1534 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0.7 | uM |
HEK293 cells
|
Normal
|
||
| Half Maximal Activity Concentration (AC50) | 0.8913 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 1 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 1.122 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 1.122 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 1.2 | uM |
HEK293 cells
|
Normal
|
||
| Half Maximal Activity Concentration (AC50) | 2.432 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 25.12 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 39.81 | uM | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 4.5 | uM |
HEK293 cells
|
Normal
|
||
| Cellular activity | 40 | uM |
HEK293 cells
|
Normal
|
||
| Cellular activity | 42 | uM |
HEK293 cells
|
Normal
|
||
| Median Effective Dose (ED50) | 5.3 | uM |
NUGC-4 cells
|
Gastric adenocarcinoma
|
||
| Median Effective Dose (ED50) | 5.3 | uM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Median Effective Dose (ED50) | 5.3 | uM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Median Effective Dose (ED50) | 5.9 | uM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Median Effective Dose (ED50) | 6.1 | uM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Median Effective Dose (ED50) | 6.1 | uM |
L6 cells
|
Normal
|
Each Antibody-drug Conjugate Related to This Payload